Crinetics Deferred Long Term Liab from 2010 to 2024
| CRNX Stock | USD 56.09 0.03 0.05% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 20.7 K | Current Value 19.7 K | Quarterly Volatility 1.6 M |
Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Interest Income of 14.1 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 4.02. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.
Crinetics | Deferred Long Term Liab |
Latest Crinetics Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Crinetics Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Crinetics Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Crinetics Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 1,969,558 | |
| Geometric Mean | 464,871 | |
| Coefficient Of Variation | 83.38 | |
| Mean Deviation | 1,554,531 | |
| Median | 3,265,000 | |
| Standard Deviation | 1,642,286 | |
| Sample Variance | 2.7T | |
| Range | 3.2M | |
| R-Value | (0.85) | |
| Mean Square Error | 800.3B | |
| R-Squared | 0.72 | |
| Significance | 0.000057 | |
| Slope | (312,568) | |
| Total Sum of Squares | 37.8T |
Crinetics Deferred Long Term Liab History
About Crinetics Pharmaceuticals Financial Statements
Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 20.7 K | 19.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.